Variant Phenotype Annotation
证据URL
https://www.pharmgkb.org/variantAnnotation/1444705000
总结
TPMT intermediate metabolizer phenotype is associated with increased likelihood of treatment modification when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT normal metabolizer phenotype.